VCM
EDIT icon

Versant Capital Management’s Editas Medicine EDIT Stock Holding History

Versant Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324 Hold
100
– – ﹤0.01% 2707
2026
Q1 		$247 Hold
100
– – ﹤0.01% 2752
2025
Q4 		$205 Hold
100
– – ﹤0.01% 2619
2025
Q3 		$347 Hold
100
– – ﹤0.01% 2587
2025
Q2 		$220 Hold
100
– – ﹤0.01% 2592
2025
Q1 		$116 Hold
100
– – ﹤0.01% 2483
2024
Q4 		$127 Hold
100
– – ﹤0.01% 2350
2024
Q3 		$341 Buy
+100
New +$435 ﹤0.01% 1910

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Versant Capital Management's EDIT Position: Q2 2026 in Review

Versant Capital Management held its Editas Medicine (EDIT) position steady in Q2 2026 at 100 shares worth $324. The position accounts for ﹤0.01% of the portfolio, ranked #2707.

Versant Capital Management first reported a position in EDIT in Q3 2024 and has held it in 8 quarters since. The position peaked at $347 in Q3 2025. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Versant Capital Management held 100 shares of Editas Medicine worth $324 as of Q2 2026.
  • Versant Capital Management left its Editas Medicine share count unchanged in Q2 2026.
  • Editas Medicine made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2707 holding.
  • Versant Capital Management first reported a position in Editas Medicine in Q3 2024 and has held it in 8 quarters since.
  • Versant Capital Management's Editas Medicine position peaked at $347 in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.